In the UK, more than a third of adults suffer from symptoms of insomnia, while over 2.5 million people experience anxiety. Typically, these are treated with medication and therapy, which can have limitations and side effects. Neurovalens is addressing these challenges by developing noninvasive and drug free treatments.
Neurovalens’ noninvasive, wearable neurostimulation device directly targets the nervous system, offering long-term relief without the side effects or risks associated with medication use. Moreover, the device’s design allows for home-based treatments that can demonstrate clinically significant improvements in patients with these conditions within just four weeks.
As the Chief Project Officer, Iain Hendrick with responsibilities spanning operations, product development, manufacturing, quality management, and business development. With Neurovalens poised for a period of significant growth and Iain aims to strengthen his leadership and skills in readiness to take the company through this period.
He aims to leverage the Shott Scale Up Accelerator for comprehensive professional development and to equip him with the skills to scale the company. He notes: “The opportunity to have access to experienced mentors and coaches as part of the Royal Academy of Engineering is an exciting opportunity to develop leadership and individual effectiveness. Expanding your network is a great way to enable collaboration and share knowledge.”
Neurovalens is poised for growth following their first medical device approval for treating insomnia in 2023 through research conducted with institutions globally including University of San Diego California, Ulster University, and Mount Sinai Hospital.
They are now looking at Series B investment and commercialisation of its medical devices to bring noninvasive and drug free treatments to patients in the US, UK, and Europe. Taking key lessons from the Shott Scale Up Accelerator will be instrumental in building the team and maintaining their core values and company culture.
